General Hematology
Case report and brief review | Severe thrombotic complications secondary to antiphospholipid syndrome and undiagnosed systemic lupus erythematosus.
20 Sep, 2022 | 13:17h | UTC
AHA Scientific Statement | Management of patients at risk for and with left ventricular thrombus.
16 Sep, 2022 | 13:00h | UTC
Review | Obesity and contraceptive use: impact on cardiovascular risk.
16 Sep, 2022 | 12:53h | UTCObesity and contraceptive use: impact on cardiovascular risk – ESC Heart Failure
News Release: Combined birth control pill linked with increased risk of blood clots in obese women – European Society of Cardiology
M-A | Blood type linked to the risk of stroke before age 60.
13 Sep, 2022 | 13:17h | UTCContribution of Common Genetic Variants to Risk of Early Onset Ischemic Stroke – Neurology (link to abstract – $ for full-text)
News Releases:
Is your blood type linked to your risk of stroke before age 60? – American Academy of Neurology
Blood Type Linked To Stroke Risk Before 60 – University of Maryland
Systematic Review | Hypoxia‐inducible factor stabilizers for the anemia of chronic kidney disease.
8 Sep, 2022 | 14:35h | UTCHypoxia‐inducible factor stabilisers for the anaemia of chronic kidney disease – Cochrane Library
48-week follow-up of a RCT | Pegcetacoplan vs. Eculizumab in patients with paroxysmal nocturnal hemoglobinuria.
8 Sep, 2022 | 14:29h | UTCPegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial – The Lancet Haematology (link to abstract – $ for full-text)
Original Study: Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria – New England Journal of Medicine
Commentary on Twitter (thread – click for more)
NEW research—Duration of improved haem outcomes and favourable safety over 48 weeks suggests that pegcetacoplan has the potential to alter treatment goals in patients with paroxysmal nocturnal haemoglobinuria: long-term results of PEGASUS #PNH https://t.co/dpT5cDih8X
— The Lancet Haematology (@TheLancetHaem) September 1, 2022
Opinion | Tranexamic acid for safer surgery: the time is now.
7 Sep, 2022 | 12:37h | UTCTranexamic acid for safer surgery: the time is now – British Journal of Surgery
Related:
Update on applications and limitations of perioperative tranexamic acid.
Brief Review | Thromboprophylaxis in critical care.
6 Sep, 2022 | 14:41h | UTCThromboprophylaxis in critical care – Intensive Care Medicine
Review | The use of whole blood transfusion in trauma.
6 Sep, 2022 | 14:15h | UTCThe Use of Whole Blood Transfusion in Trauma – Current Anesthesiology Reports
Systematic Review | Hydroxyurea for sickle cell disease.
5 Sep, 2022 | 14:14h | UTCHydroxyurea (hydroxycarbamide) for sickle cell disease – Cochrane Library
Summary: Hydroxyurea (also known as hydroxycarbamide) for people with sickle cell disease – Cochrane Library
Systematic Review | The effect of heparin and its preparations on disseminated intravascular coagulation mortality and hospitalization.
1 Sep, 2022 | 11:34h | UTC
#ESCCongress | In critically ill patients with COVID-19, full-dose anticoagulation reduced thrombotic events but increased the risk of bleeding.
30 Aug, 2022 | 12:12h | UTCNews Release: Trial supports full-dose anticoagulation to prevent blood clots in COVID-19 patients – European Society of Cardiology
Related:
Anticoagulants for people hospitalised with COVID‐19 – Cochrane Library
Commentary on Twitter
#OriginalResearch SimPub #ESCCongress: In the #COVID-PACT 2×2 factorial RCT, full-dose prophylactic anticoagulation, but not the addition of clopidogrel, reduced thrombotic complications but w/ increased bleeding among critically-ill patients w/ COVID-19 https://t.co/UNxFCIC5B9 pic.twitter.com/p5LGmpCGeL
— Circulation (@CircAHA) August 29, 2022
#ESCCongress – RCT | In patients with rheumatic heart disease–associated atrial fibrillation, treatment with a Vitamin K antagonist led to a lower rate of cardiovascular events or death compared to Rivaroxaban.
29 Aug, 2022 | 12:33h | UTCRivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Trial backs standard of care for rheumatic heart disease and atrial fibrillation – European Society of Cardiology
Commentary: INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF – TCTMD
Commentary on Twitter
INVICTUS: In patients with RHD-associated AF, compared to rivaroxaban, VKA reduced cardiovascular events and mortality without increasing bleeding. #ESCCongress https://t.co/4C45LmmB5o pic.twitter.com/9n3OelzZvp
— NEJM (@NEJM) August 28, 2022
Review | Blood transfusion reactions.
23 Aug, 2022 | 12:50h | UTC
Single-arm phase 2 study | Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent alpha-thalassaemia or beta-thalassaemia.
18 Aug, 2022 | 12:40h | UTCSafety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent α-thalassaemia or β-thalassaemia: an open-label, multicentre, phase 2 study – The Lancet (link to abstract – $ for full-text)
Commentary: PK Modulator Shows Promise in Thalassemia — In small study, mitapivat increased hemoglobin in 80% of non-transfusion-dependent patients – MedPage Today (free registration required)
Guideline | Use of COVID-19 convalescent plasma.
17 Aug, 2022 | 14:28h | UTC
M-A | Efficacy and safety of heparin full-dose anticoagulation in hospitalized non-critically ill COVID-19 patients.
15 Aug, 2022 | 12:27h | UTCRelated:
Anticoagulants for people hospitalised with COVID‐19 – Cochrane Library
Review | Plasma exchange in the intensive care unit.
15 Aug, 2022 | 12:19h | UTCPlasma exchange in the intensive care unit: a narrative review – Intensive Care Medicine
Commentary on Twitter
Therapeutic plasma exchange in #ICU
🟨 indications for urgent TPE
🟨 mechanisms, kinetics and therapeutic goals
🟨 diagnostic workup & monitoring
🟨 technical aspects
🟨 clinical response & complications
🟨 unanswered questions & research agenda#FOAMcc
📎 https://t.co/CojkcA81Dy pic.twitter.com/MsAdjgJhNL— Intensive Care Medicine (@yourICM) August 13, 2022
Consensus Guidance | Thromboprophylaxis for venous thromboembolism prevention in hospitalized patients with cirrhosis.
12 Aug, 2022 | 14:54h | UTC
Review | Thrombotic microangiopathy in children.
5 Aug, 2022 | 13:56h | UTCThrombotic microangiopathy in children – Pediatric Nephrology (if the link is paywalled, try this one)
Cohort Study | Incidence of acute chest syndrome in children with sickle cell disease following implementation of the 13-valent pneumococcal conjugate vaccine.
3 Aug, 2022 | 13:53h | UTC
Commentary on Twitter
#OrigInvestigation: Reduction of acute chest syndrome incidence in children with sickle-cell disease following 13-valent pneumococcal conjugate vaccine (PCV13) implementation in France. https://t.co/MuG6T0g5FU
— JAMA Network Open (@JAMANetworkOpen) August 2, 2022
Systematic Review | Stem cell transplantation for systemic sclerosis.
1 Aug, 2022 | 12:10h | UTCStem cell transplantation for systemic sclerosis – Cochrane Library
Summary: Stem cell transplantation for the treatment of systemic sclerosis – Cochrane Library
Systematic Review | Antiplatelet agents for the treatment of deep venous thrombosis.
26 Jul, 2022 | 12:44h | UTCAntiplatelet agents for the treatment of deep venous thrombosis – Cochrane Library
Summary: Aspirin and similar drugs for the treatment of deep vein thrombosis (DVT) – Cochrane Library
RCT | Ticagrelor is ineffective for reducing vaso-occlusive crises in pediatric sickle cell disease.
25 Jul, 2022 | 12:50h | UTC
EASL Clinical Practice Guidelines on hemochromatosis.
18 Jul, 2022 | 11:47h | UTCEASL Clinical Practice Guidelines on haemochromatosis – Journal of Hepatology